Document Detail


Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract.
MedLine Citation:
PMID:  15289814     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Recommendations regarding the use of plant-derived medications for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) state that every brand should be fully evaluated and considered separately. Disparity between a number of brands in terms of their stated and actual doses has been recently highlighted. The aim of this study was to fully quantify the variation in Serenoa repens extracts (SrE) commercially available for the treatment of BPH-associated LUTS. To this end, 14 brands of SrE were compared. Concentrations of free fatty acids (FFAs), methyl and ethyl esters, long-chain esters and glycerides were assessed using liquid and gas chromatography. Many of the brands showed a significantly different proportional content which may have an impact on their clinical efficacy and safety. The high concentrations of FFAs in particular, which previous research has suggested as comprising the active agent of SrE for the treatment of LUTS, may influence the clinical benefit derived from each product. Our findings lend further weight to recommendations by the 5th International Consultation on BPH that plant-derived treatments should be analysed and considered as independent entities despite their common origin. Only extracts with demonstrated pharmacological activities and proven clinical efficacy should be considered for the treatment of patients with BPH.
Authors:
F K Habib; M G Wyllie
Related Documents :
8508634 - The allergenicity of glycerol esters and other esters of rosin (colophony).
9194 - Antifungal properties of alpha,omega-alkanedicarboxylic acids and their dimethyl esters.
3133344 - Antimycoplasmal activities of the pseudomonic acids and structure-activity relationship...
12450674 - Chromatographic methods for the determination of markers of chronic and acute alcohol c...
1966904 - A study of ozone-induced edema in the isolated rat lung in relation to arachidonic acid...
8508634 - The allergenicity of glycerol esters and other esters of rosin (colophony).
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Prostate cancer and prostatic diseases     Volume:  7     ISSN:  1365-7852     ISO Abbreviation:  Prostate Cancer Prostatic Dis.     Publication Date:  2004  
Date Detail:
Created Date:  2004-09-02     Completed Date:  2005-03-01     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9815755     Medline TA:  Prostate Cancer Prostatic Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  195-200     Citation Subset:  IM    
Affiliation:
Prostate Research Group, University Department of Oncology, Western General Hospital, Edinburgh, UK. f.k.habib@ed.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Humans
Male
Phytotherapy*
Plant Extracts / chemistry,  therapeutic use*
Prostatic Hyperplasia / complications*,  drug therapy
Serenoa*
Urinary Tract Infections / drug therapy*
Chemical
Reg. No./Substance:
0/Plant Extracts

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Epithelial stem cells in human prostate growth and disease.
Next Document:  Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsyc...